On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Big Ideas on Burnout: Trainees Propose System-Wide Solutions

The Special Symposium on Quality at the 2020 ASH Annual Meeting tackled an often-overlooked driver of quality of patient care: burnout. Physician burnout –...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
On location

FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia

Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Does High-Dose Methotrexate Protect the Central Nervous System in High-Risk DLBCL?

A retrospective study found that treatment with high-dose methotrexate did not lower the risk of central nervous system (CNS) relapse in patients with high-risk...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
On location

BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma

In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
On location

Avatrombopag Demonstrates Efficacy in ITP, Regardless of Prior Treatment

Treatment with the thrombopoietin receptor agonist (TPO-RA) avatrombopag led to durable platelet count responses in patients with immune thrombocytopenia (ITP), with responses among both...
On location

New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in Most Patients

A single dose of the gene therapy drug etranacogene dezaparvovec increased factor IX (FIX) activity levels, and eliminated the need for prophylactic FIX, in...
Advertisement

Current Issue

January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.

Block title